{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":43,"n_cols":5,"rows_kept":43,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[13,2,13,3],[14,2,14,3],[18,2,18,3],[23,2,23,3],[23,4,23,5],[24,2,24,3],[24,4,24,5],[25,2,25,3],[26,2,26,3],[30,2,30,3],[31,2,31,3],[32,2,32,3],[36,2,36,3],[37,2,37,3],[41,2,41,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910451015403321"]
[null,null,"Titolo",null,"The dialogical self in psychotherapy / / edited by Hubert J.M. Hermans and Giancarlo Dimaggio"]
[null,null,"Pubbl/distr/stampa",null,"Hove, East Sussex ; ; New York : , : Brunner-Routledge, , 2004"]
[null,null,"ISBN",null,"1-135-44655-5"]
[{"$nulls":4},"1-280-10186-5"]
[{"$nulls":4},"9786610101863"]
[{"$nulls":4},"0-203-31461-1"]
[null,null,"Descrizione fisica",null,"1 online resource (293 p.)"]
[null,null,"Classificazione",null,"77.52"]
[null,null,"Disciplina",null,"616.89/14"]
[null,null,"Soggetti",null,"Self"]
[{"$nulls":4},"Psychotherapy"]
[{"$nulls":4},"Electronic books."]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Book Cover; Title; Contents; List of illustrations; Notes on contributors; The dialogical self in psychotherapy: introduction; General theory; The dialogical self: between exchange and power; Developmental origins of the dialogical self: some significant moments; Toward a neuropsychological model of internal dialogue: implications for theory and clinical practice; Encountering self-otherness: 'I-I' and 'I-Me' modes of self-relating; Theory and clinical practice; Self-multiplicity and narrative expression in psychotherapy"]
[{"$nulls":4},"Encounters between internal voices generate emotion: an elaboration of the assimilation modelFrom discord to dialogue: internal voices and the reorganization of the self in process-experiential therapy; The dialogical construction of coalitions in a personal position repertoire; Standing in the spaces: the multiplicity of self and the psychoanalytic relationship; The psychodramatic 'social atom method' with children: a developing dialogical self in dialectic action; Reconstructing dialogical processes in severely affected patients"]
[{"$nulls":4},"Performing the self: therapeutic enactment and the narrative integration of traumatic lossStrategies for the treatment of dialogical dysfunctions; Dialogical transformation in the psychotherapy of schizophrenia; A dialogical approach to patients with personality disorders; Methodological issues in the psychotherapeutic process; "]
[{"$nulls":4},"Hearing voices: methodological issues in measuring internal multiplicity; Dialogical sequence analysis; Index"]
[null,null,null,"Sommario/riassunto","How can a theory of the self be used to understand the psychotherapeutic process? The basic assumption of the 'dialogical self' is that there is no centralised 'headquarter' in the mind, but that the internal self is made up of a number of different 'characters'. Interpersonal relationships, from infancy onwards, become internalised - these internalised relationships then influence relationships during life. The Dialogical Self in Psychotherapy is divided into four clear and accessible sections, which explore: * theoretical and historical assumptions of the dia"]
[null,"2.","Record Nr.",null,"UNINA9910139507003321"]
[null,null,"Titolo",null,"Critical pathways to success in CNS drug development [[electronic resource] /] / Neal R. Cutler ... [et al.]"]
[null,null,"Pubbl/distr/stampa",null,"Chichester, UK ; ; Hoboken, NJ, : Wiley-Blackwell, 2010"]
[null,null,"ISBN",null,"1-282-49126-1"]
[{"$nulls":4},"9786612491269"]
[{"$nulls":4},"1-4443-1857-8"]
[{"$nulls":4},"1-4443-1858-6"]
[null,null,"Descrizione fisica",null,"1 online resource (273 p.)"]
[null,null,"Disciplina",null,"615"]
[null,null,"Soggetti",null,"Neuropsychopharmacology"]
[{"$nulls":4},"Drug development"]
[{"$nulls":4},"Critical path analysis"]
[{"$nulls":4},"Central nervous system - Effect of drugs on - Research - Methodology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Critical Pathwaysto Success in CNSDrug Development; Contents; Acknowledgments; Foreword; 1 The impending crisis in CNS drug development; 2 Animal models and procedures for CNS disorders; 3 Preclinical antecedents to early human clinical trials; 4 Biomarkers and surrogate markers in drug development; 5 Neuroimaging and cognitive assessments in early drug development; 6 Bridging and CSF studies; 7 A case study from preclinical to early clinical trials; Index"]
[null,null,null,"Sommario/riassunto","Covering the latest advances in CNS drug development, this book will guide all those involved in pre-clinical to early clinical trials. The authors describe how recent innovations can accelerate the development of novel CNS compounds, improve early detection of efficacy and toxicity signals, and increase the safety of later-stage clinical trials. The current crisis in the drug development industry is critically reviewed, as well as the steps needed to correct the problems, including new government-backed regulations and industry-based innovations designed to accelerate CNS drug development i"]